目的 建立人胰腺癌细胞株BXPC-3裸鼠皮下瘤、腹腔内种植转移瘤以及原位移植瘤模型,探讨模型建立方法及其生物学特性.方法 采用直接皮下瘤细胞注射法建立胰腺癌裸鼠皮下瘤模型,开腹后瘤块包埋法建立腹腔内种植转移瘤模型,瘤细胞悬液置入胰腺包膜下建立原位移植模型,观察三种模型接种阳性率及瘤块生长的速度,对移植瘤做病理检查.结果 3种模型构建的阳性率分别为:皮下瘤模型47％(7/15),腹腔种植转移瘤模型100％(14/14),原位移植模型100％ (14/14).后两种模型1月后发生肝转移、腹膜转移、肠系膜转移,3组间肿瘤生长速度比较,原位移植模型最快,腹腔种植转移模型其次,皮下瘤模型最慢,差异具有统计学意义(P＜0.01).病理检查符合胰腺低分化腺癌.结论 成功建立了胰腺癌BXPC-3细胞株的皮下移植瘤模型、腹腔种植转移模型及原位移植模型,显示了各种模型的独特优势,为胰腺癌生物学行为的基础研究及治疗提供了实验平台.%To establish models of subcutaneous tumor, intra-abdominal metastasis tumor and in situ xenograft in nude mice with human pancreatic cancer cell line BXPC-3 to discuss the modeling methods and the biological characteristics of human pancreatic cancer model in nude mice. Methods Subcutaneous pancreatic tumor model was established by direct subcutaneous injection of human tumor cells in nude mice. Intra-abdominal metastasis tumor model was established by embedding tumor blocks in nude mice after laparotomy. Tumor orthotopic transplantation model was established by injecting tumor cell suspension into pancreatic capsules in nude mice. We observed all the three models for the positive rate of tumor inoculation and growth rate of tumor size, and then made pathological examination of the tumor. Results The positive rate of construction of the three models is as follows: 47% (7/15) for subcutaneous model, 100% (14/14) for tumor blocks embedded peritoneal metastatic tumor model, and 100% (14/14) for orthotopic model. The latter two models presented liver metastasis, peritoneal metastasis and mesenteric metastasis one month later. The rates of tumor formation in the three groups had significant differences (P<0.01). Pathological results accorded with poorly differentiated adenocarcinoma of the pancreas. Conclusion We have successfully established the models of subcutaneous tumor, intra-abdominal metastasis tumor and in situ xenograft in nude mice with human pancreatic cancer cell line BXPC-3. Different models show their unique advantages, which provides an experimental platform for basic research of the biological behavior of human pancreatic cancer and its treatment.
展开▼
